IRWD Nov 2024 5.000 put
OPR - OPR Delayed Price. Currency in USD
Add to watchlist
As of 09:30AM EDT. Market open.
| Previous Close | 0.5700 |
| Open | 0.5700 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 5.00 |
| Expire Date | 2024-11-15 |
| Day's Range | 0.5700 - 0.5700 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 21 |
Business WireIronwood Late-Breaker Oral Presentation at Digestive Disease Week® Reinforces Potential of Once-Weekly Apraglutide for Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF)
BOSTON, May 21, 2024--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, will present late-breaking data during the 2024 Digestive Disease Week® (DDW) meeting from its pivotal Phase III clinical trial, STARS, which evaluated the efficacy and safety of once-weekly subcutaneous apraglutide in adult patients with short bowel syndrome with intestinal failure (SBS-IF). These findings build on the positive topline data that Ironwood previously announced in February 2024. B
Simply Wall St.US$16.33: That's What Analysts Think Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Is Worth After Its Latest Results
It's been a sad week for Ironwood Pharmaceuticals, Inc. ( NASDAQ:IRWD ), who've watched their investment drop 14% to...
- GuruFocus.com
Ironwood Pharmaceuticals Reports Mixed Q1 2024 Results Amid Key Clinical Advancements
Revenue Falls Short of Expectations While Clinical Trials Show Promising Outcomes
© 2024 Yahoo. All rights reserved.